Home Biosimilar Antibodies TGF-beta/Smad TGF-beta/Smad Anti-TGFb1 (NIS793)
For research use only. Not for use in humans.

Anti-TGFb1 (NIS793)

Synonyms: NIS793

Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD

Anti-TGFb1 (NIS793)

Quality Control

Batch: A307101 Purity: 99% Protein concentration: 5.403mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation ALK1 ALK2 ALK3 ALK4 TGFβRI/ALK5 ALK6 TGFβRII TGF-β Smad3 ALK7 Others
SB431542 826
LDN-193189 278
Galunisertib (LY2157299) 193
LY2109761 138
SB-525334 120
SB505124 37
GW788388 26
LY364947 49 RIPK2,CK1δ,MLK-7K
RepSox (E-616452) 86
LDN-193189 Dihydrochloride 108
K02288 25
TGFβRI-IN-3 2
R-268712 1
BIBF-0775 0
TP0427736 HCl 6
A-83-01 75
LDN-214117 4
SD-208 23
Vactosertib (TEW-7197) 29
ML347 5
LDN-212854 8
DMH1 63
Dorsomorphin Dihydrochloride 515 AMPK
PF-06952229 0
Ginsenoside Rh4 0
SIS3 17
AUDA 1 TNF-α,IL-1β,MMP-9
PD 169316 2 Activin A,Enterovirus71,p38 MAPK
TA-02 0 p38 MAPK
ITD-1 15
LY 3200882 7
Alantolactone 3 STAT3
Halofuginone 13 prolyl-tRNA synthetase
SIS3 Hydrochloride 86
Dorsomorphin (Compound C) 478 AMPK
Hesperetin 4 Histamine receptor
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD
References

Product Details

Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04952753 TERMINATED Drug: NIS793|Drug: Bevacizumab|Drug: Modified FOLFOX6|Drug: Metastatic Colorectal Cancer Novartis Pharmaceuticals 2021-11-15 PHASE2
NCT04935359 COMPLETED Drug: NIS793|Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: Pl Metastatic Pancreatic Ductal Adenocarcinoma Novartis Pharmaceuticals 2021-09-30 PHASE3
NCT04390763 TERMINATED Drug: gemcitabine|Drug: nab-paclitaxel Metastatic Pancreatic Ductal Adenocarcinoma Novartis Pharmaceuticals 2020-10-16 PHASE2
NCT04810611 TERMINATED Drug: MBG453|Drug: NIS793|Drug: canakinumab Myelodysplastic Syndromes Novartis Pharmaceuticals 2021-06-18 PHASE1
NCT04283526 WITHDRAWN Drug: MBG453|Drug: NIS793|Drug: Spartalizumab|Drug: Decitabi Primary Myelofibrosis; Myelofibrosis; PMF; Post-Essential Thrombocythemia Myelofibrosis; Post-Polycythemia Vera Myelofibrosis Novartis Pharmaceuticals 2020-11-30 PHASE1
NCT05546411 TERMINATED Drug: mFOLFIRINOX|Drug: 5-Fluorouracil (5-FU)|Drug: Oxalipla Pancreatic Cancer; Resectable Pancreatic Cancer; Borderline Resectable Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Kimberly Perez, MD 2023-01-06 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-03-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.